Overview

Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT

Status:
Completed
Trial end date:
2019-03-30
Target enrollment:
Participant gender:
Summary
The objective of the study is to evaluate evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid in the treatment of subjects with open-angle glaucoma or ocular hypertension
Phase:
Phase 3
Details
Lead Sponsor:
Ocular Therapeutix, Inc.
Treatments:
Travoprost